Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MR-proADM as a Early Biomarker for DGF and AR in Kidney and Liver Transplantation

NCT06130046 is registered in ClinicalTrials.gov with University of Rome Tor Vergata as lead sponsor.

NCT NCT06130046
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06130046 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MR-proADM as a Early Biomarker for DGF and AR in Kidney and Liver Transplantation
Lead sponsor
University of Rome Tor Vergata
Phase
Observational
Overall status
Recruiting
Start date
December 1, 2022
Completion date
December 1, 2026
Enrollment
300 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

kidney transplant; complications, liver transplant; complications